81 related articles for article (PubMed ID: 11870553)
1. (99m)Tc-labelled Stealth liposomal doxorubicin (Caelyx) in glioblastomas and metastatic brain tumours.
Laverman P; Boerman OC; Storm G; Oyen WJ
Br J Cancer; 2002 Feb; 86(4):659-61. PubMed ID: 11870553
[No Abstract] [Full Text] [Related]
2. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours.
Koukourakis MI; Koukouraki S; Fezoulidis I; Kelekis N; Kyrias G; Archimandritis S; Karkavitsas N
Br J Cancer; 2000 Nov; 83(10):1281-6. PubMed ID: 11044350
[TBL] [Abstract][Full Text] [Related]
3. High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with (99m)Tc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin.
Arrieta O; Medina LA; Estrada-Lobato E; Ramírez-Tirado LA; Mendoza-García VO; de la Garza-Salazar J
Cancer Chemother Pharmacol; 2014 Jul; 74(1):211-5. PubMed ID: 24817602
[TBL] [Abstract][Full Text] [Related]
4. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes.
Symon Z; Peyser A; Tzemach D; Lyass O; Sucher E; Shezen E; Gabizon A
Cancer; 1999 Jul; 86(1):72-8. PubMed ID: 10391566
[TBL] [Abstract][Full Text] [Related]
5. Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma.
Lakkadwala S; Dos Santos Rodrigues B; Sun C; Singh J
J Control Release; 2019 Aug; 307():247-260. PubMed ID: 31252036
[TBL] [Abstract][Full Text] [Related]
6. Combination radiofrequency ablation and intravenous radiolabeled liposomal Doxorubicin: imaging and quantification of increased drug delivery to tumors.
Head HW; Dodd GD; Bao A; Soundararajan A; Garcia-Rojas X; Prihoda TJ; McManus LM; Goins BA; Santoyo CA; Phillips WT
Radiology; 2010 May; 255(2):405-14. PubMed ID: 20413753
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl).
Working PK; Dayan AD
Hum Exp Toxicol; 1996 Sep; 15(9):751-85. PubMed ID: 8880211
[No Abstract] [Full Text] [Related]
8. Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies.
Bao A; Goins B; Klipper R; Negrete G; Phillips WT
J Pharmacol Exp Ther; 2004 Feb; 308(2):419-25. PubMed ID: 14610219
[TBL] [Abstract][Full Text] [Related]
9. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas--rationale for combination with radiotherapy.
Koukourakis MI; Koukouraki S; Giatromanolaki A; Kakolyris S; Georgoulias V; Velidaki A; Archimandritis S; Karkavitsas NN
Acta Oncol; 2000; 39(2):207-11. PubMed ID: 10859012
[TBL] [Abstract][Full Text] [Related]
10. Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer.
Tejada-Berges T; Granai CO; Gordinier M; Gajewski W
Expert Rev Anticancer Ther; 2002 Apr; 2(2):143-50. PubMed ID: 12113236
[TBL] [Abstract][Full Text] [Related]
11. Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase.
Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Yang H
J Pharm Pharmacol; 2008 Dec; 60(12):1651-7. PubMed ID: 19000370
[TBL] [Abstract][Full Text] [Related]
12. Treating glioblastoma multiforme with selective high-dose liposomal doxorubicin chemotherapy induced by repeated focused ultrasound.
Yang FY; Teng MC; Lu M; Liang HF; Lee YR; Yen CC; Liang ML; Wong TT
Int J Nanomedicine; 2012; 7():965-74. PubMed ID: 22393293
[TBL] [Abstract][Full Text] [Related]
13. Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer.
Ranson MR; Cheeseman S; White S; Margison J
Crit Rev Oncol Hematol; 2001 Feb; 37(2):115-20. PubMed ID: 11166584
[TBL] [Abstract][Full Text] [Related]
14. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
[TBL] [Abstract][Full Text] [Related]
15. Complete resolution of psoriasis in a patient treated with stealth liposomal doxorubicin and carboplatin for ovarian cancer.
Pisano C; Tambaro R; Di Maio M; Formato R; Iaffaioli VR; Pignata S
Arch Dermatol Res; 2004 Aug; 296(3):141-2. PubMed ID: 15278368
[No Abstract] [Full Text] [Related]
16. [Intracellular accumulation of free doxorubicin and doxorubicin encapsulated in nanospheres].
Bogush TA; Smirnova GB; Shubina IZh; Bogush EA; Robert J
Biull Eksp Biol Med; 1994 Oct; 118(10):406-9. PubMed ID: 7865821
[No Abstract] [Full Text] [Related]
17. Characterization and pharmacokinetics of a novel pirarubicin liposome powder.
Cong W; Liu Q; Chen X; Gao R; Lu J; Wang Y; Luo G
Drug Dev Ind Pharm; 2010 Oct; 36(10):1186-94. PubMed ID: 20515395
[TBL] [Abstract][Full Text] [Related]
18. Integrins as target: first phase III trial launches, but questions remain.
Carter A
J Natl Cancer Inst; 2010 May; 102(10):675-7. PubMed ID: 20460633
[No Abstract] [Full Text] [Related]
19. Infusion rates and drug distribution in brain tumor models in rats.
Khan A; Jallo GI; Liu YJ; Carson BS; Guarnieri M
J Neurosurg; 2005 Jan; 102(1 Suppl):53-8. PubMed ID: 16206734
[TBL] [Abstract][Full Text] [Related]
20. A tracer dose of technetium-99m-labeled liposomes can estimate the effect of hyperthermia on intratumoral doxil extravasation.
Kleiter MM; Yu D; Mohammadian LA; Niehaus N; Spasojevic I; Sanders L; Viglianti BL; Yarmolenko PS; Hauck M; Petry NA; Wong TZ; Dewhirst MW; Thrall DE
Clin Cancer Res; 2006 Nov; 12(22):6800-7. PubMed ID: 17121901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
